Abiopharma

🔍 Sheena Jonathan (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2025-06-16

Detailed Transactions and Holdings:

• Sold 3,070 shares of Common Stock at $167.2869 per share (Direct)
  Date: 2025-06-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 248,774.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 200 shares of Common Stock at $162.4968 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,582.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5
• Sold 203 shares of Common Stock at $163.4069 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,379.00 | transaction_form_type: 4 | Footnotes: F3, F6, F5
• Sold 550 shares of Common Stock at $164.8073 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,829.00 | transaction_form_type: 4 | Footnotes: F3, F7, F5
• Sold 547 shares of Common Stock at $165.4829 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,282.00 | transaction_form_type: 4 | Footnotes: F3, F8, F5
• Sold 176 shares of Common Stock at $162.5178 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,606.00 | transaction_form_type: 4 | Footnotes: F3, F9, F5
• Sold 200 shares of Common Stock at $163.1 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,406.00 | transaction_form_type: 4 | Footnotes: F3, F10, F5
• Sold 425 shares of Common Stock at $164.6398 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,981.00 | transaction_form_type: 4 | Footnotes: F3, F11, F5
• Sold 699 shares of Common Stock at $165.4079 per share (Direct)
  Date: 2025-06-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,282.00 | transaction_form_type: 4 | Footnotes: F3, F12, F5

Footnotes:

• F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.7250 to $167.6950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.58 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
• F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.12 to $163.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.45 to $165.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.48 to $165.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.08 to $163.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F11: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.10 to $165.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F12: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.16 to $165.55 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.